In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocon Ltd.

www.biocon.com

Latest From Biocon Ltd.

Insulin Biosimilars: US FDA Hears Wide Range Of Views From Small Set Of Sponsors

US FDA heard a predictably wide range of advice on the appropriate standards for approving biosimilar and interchangeable insulin during a public hearing on the topic. What is surprising is how few sponsors decided to speak out.

Biosimilars Metabolic Disorders

Best Pathway To Interchangeable Insulins Is In The Eye Of The Beholder

Approaches suggested at a US FDA public hearing include allowing follow-on insulins to take a direct route to interchangeability without first having to be approved as biosimilars, and automatically declaring biosimilar insulins interchangeable with one or more reference products.

Biosimilars Biologics

A Guide To US FDA’s Drug-To-Biologic Transition Process

As agency's hearing approaches, a Pink Sheet graphic charts the path for pending and approved applications for insulin, human growth hormone, and certain other protein products when the BPCIA ‘transition provisions’ take effect in March 2020.

Biosimilars Biologics

Biocon Biologics Reaches Landmark Sales Figure As IPO Beckons

Biocon rang in a strong fourth quarter amid signs of a build-up in efforts towards supporting the “independent functioning” of its biosimilars business under subsidiary Biocon Biologics.

India Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Medical Devices
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Biocon Ltd.
  • Senior Management
  • Arun Chandavarkar, PhD, CEO
    Siddharth Mittal, CFO
    Ravi Limaye, Pres., Mktg.
    Narendra Chirmule, PhD, SVP & Head, R&D
  • Contact Info
  • Biocon Ltd.
    Phone: (91) 80 2808 2808
    20th KM Hosur Rd.
    Electronic City
    Bangalore , 560 100
    India
Advertisement
Advertisement
UsernamePublicRestriction

Register